Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71081 | 1.00 | SGMS2 (0.67) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| SCHEMBL8277221 | 0.90 | GAA (0.62) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| SCHEMBL10102482 | 0.89 | RXRA (0.68) | SGMS2SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL30535305 | 0.88 | SGMS2 (0.57) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| Boric Acid SCHEMBL27963894 | 0.88 | SGMS2 (0.55) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| SCHEMBL27914187 | 0.87 | PTGER1 (0.66) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| SCHEMBL8489879 | 0.87 | MAPT (0.57) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| SCHEMBL8088242 | 0.87 | MAOB (0.63) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| Acetophenone SCHEMBL164169 | 0.86 | LMNA (0.55) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 | |
| SCHEMBL34466860 | 0.85 | TDP1 (0.56) | SGMS2SMN1; SMN2MAPTL3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119923385-A | Inhibitors of RNA helicase DHX9 and uses thereof | 埃克森特治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4436965-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| CN-118574827-A | BRM targeting compounds and related methods of use | 阿维纳斯运营公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | SGMS2 4133/4885SMN1; SMN2 662/4885MAPT 3914/4885 |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | SGMS2 3774/4885SMN1; SMN2 536/4885MAPT 3967/4885 |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | SGMS2 4133/4885SMN1; SMN2 662/4885MAPT 3914/4885 |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | SGMS2 3774/4885SMN1; SMN2 536/4885MAPT 3967/4885 |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | GLI1, RCC2, BRCA1 | SGMS2 1600/4885SMN1; SMN2 305/4885MAPT 418/4885 |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | SGMS2 4112/4885SMN1; SMN2 645/4885MAPT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.